Biotech · Public company · Houston, TX, US

Moleculin Biotech, Inc.

Ticker MBRX · SEC CIK 0001659617

Track this companyFree. Adds Moleculin Biotech, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials42 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

Liposomal Annamycin for Injection in combination with Cytarabine Injection.Phase 3 · Acute Myeloid Leukaemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
Liposomal Annamycin Injection in combination with Cytarabine InjectionPhase 3 · Acute Myeloid Leukaemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
Liposomal AnnamycinPhase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
Liposomal Annamycin (L-Annamycin)Phase 2 · Sarcoma,Soft TissueClinicalTrials.gov · fetched Nov 12, 2026

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLPHASE2_PHASE3 · RECRUITING · started Mar 12, 2025ClinicalTrials.gov NCT06788756 · fetched Nov 12, 2026
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaPHASE2 · RECRUITING · started May 22, 2024ClinicalTrials.gov NCT05879250 · fetched Nov 12, 2026
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary MetastasesPHASE1_PHASE2 · COMPLETED · started Jun 5, 2021ClinicalTrials.gov NCT04887298 · fetched Nov 12, 2026
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · COMPLETED · started Mar 28, 2018ClinicalTrials.gov NCT03315039 · fetched Nov 12, 2026